Methods: A total of 135 eligible patients were identified, of whom 55 (44%) were randomised. Eligible patients had sustained hypertension, with a minimum diastolic BP of 95 mm Hg on at least two anti-hypertensive drugs. Renal artery stenosis was defined by renal angiography as at least 50% stenosis in the affected vessel. All patients were observed during an initial 4-week run-in period on a fixed drug regimen and subsequent changes measured from this 4-week baseline. Results: Blood pressure fell during the run-in period in all groups. In patients with bilateral renal artery stenosis randomised to angioplasty, a statistically significant (P Ͻ 0.05) fall in BP was observed at latest follow-up (range 3-54 months). The mean fall in BP at latest follow-
Introduction
Renal artery stenosis is an important finding in hypertensive patients for a number of reasons. It may predispose to or aggravate the hypertension. It may contribute to deteriorating renal function. It may render the hypertension refractory to drug treatment and it may enhance the nephrotoxicity of antihypertensive drugs. Atheromatous stenosis is accompanied by atheroma elsewhere and is associated with a considerable morbidity and mortality from stroke, coronary heart disease and peripheral vascular disease. 1 up in the angioplasty group, corrected for the medical group response, was 26/10 mm Hg. In patients with unilateral renal artery stenosis, no statistically significant or clinically important differences in outcome were observed between the two groups. No significant differences or trends in serum creatinine were observed between or within any group during follow-up. Major outcome events (death, myocardial infarction, heart failure, stroke, dialysis) were similar in the angioplasty and medical groups during follow-up. In the 40/135 patients undergoing angioplasty, serious or potentially serious complications attributable to the procedure were observed in 11 patients, bleeding at the arterial site (8 patients) being the most frequent. Conclusions: In hypertensive patients with atheromatous renal artery stenosis, percutaneous renal angioplasty results in a modest improvement in systolic BP compared with medical therapy alone. This benefit was confined to patients with bilateral disease. No patient was 'cured', renal function did not improve, and intervention was accompanied by a significant complication rate.
blood pressure (BP) control. In fibromuscular dysplasia the results of observational studies of reconstructive surgery 2 or percutaneous transluminal angioplasty (PCTA) 3 are sufficiently impressive to suggest that intervention should be attempted in most cases. PCTA is the less invasive option, has a high technical success rate, and results in cure or improvement of the hypertension in a substantial proportion of such patients. By contrast, in atheromatous renal artery disease, technical success is less likely, complications are more frequent and benefits in respect of improved BP control or preserved renal function are much smaller. 4, 5 Several commentators have emphasised the desirability of prospective controlled trials to establish the role of interventional techniques in such patients. 6, 7 A randomised, multicentre clinical trial was designed with the primary aim of determining if intervention, or continued medical therapy, resulted
Patients and methods
A total of 135 eligible patients with hypertension and renovascular disease were identified in the eight participating centres, of whom 55 (44%) were randomised. All randomised patients gave informed written consent. The non-randomised patients were managed by the preferred local option but were assessed and followed up by the same protocol as the randomised patients.
Inclusion criteria
Patients were eligible if they were known to have sustained hypertension, with a minimum diastolic BP of 95 mm Hg on treatment with at least two antihypertensive drugs. All patients underwent selective renal angiography and patients were stratified according to whether the disease was radiologically bilateral (stenosis of 50% or greater in arteries to both kidneys or in the artery to a solitary functioning kidney) or unilateral (stenosis of 50% or greater in one renal artery and less than 50% stenosis on the contralateral side). All patients were considered to have atheromatous disease on the basis of the angiographic appearances of the abdominal aorta.
Exclusions
Patients were excluded from randomisation if they were under the age of 40 (as a further measure to include only atheromatous disease). Initially patients over 70 years were also excluded, though the upper age limit was later increased to 75. Other prespecified exclusions were serum creatinine Ͼ 500 mcmol/l, or a history of stroke or myocardial infarction within the previous 3 months.
Run-in period
After satisfying the inclusion criteria, patients were randomly allocated to either intervention or continued medical therapy. All patients were then required to undergo a 4-week run-in period on a fixed anti-hypertensive drug regimen. Prior to this, drug therapy had been individualised for each patient. The recommended regimen was atenolol, bendrofluazide and a calcium antagonist, in any combination of at least two of these. Permitted alternatives included frusemide, methyldopa or prazosin. Angiotensin-converting enzyme inhibitors were not allowed. During the run-in period, patients were seen at 2 and 4 weeks. The 4-week values were used as the 'baseline' against which subsequent measurements were compared. Aspirin was recommended for all patients who could tolerate this drug.
Angiography
The angiographic appearances were classified locally and copy films were sent for independent verification by another radiologist. Angiograms where the interpretation was in doubt were also viewed by the Steering Committee. A semiquantitative assessment of the degree of stenosis was performed at baseline. The degree of stenosis of each renal artery was given a score that was summed to give a single value for each patient (0 = normal, 1 Ͻ20% stenosis, 2 = 20-49% stenosis, 3 = 50-79% stenosis, 4 = 80-99% stenosis, 5 = occluded). Thus the grading of patients in the study varied from 3 (50-79% stenosis on one side only) to 10 (bilateral occlusion).
Repeat angiograms were classified by the radiologist in the same way as at presentation but without knowledge of the initial appearances and categorised by the co-ordinating office staff as 'better', 'worse', or 'unchanged'.
Intervention
PCTA was the preferred first-line procedure in the intervention group. Alternative procedures such as nephrectomy or bypass surgery were allowed at the discretion of the local investigator, as were additional procedures during follow-up if this were thought clinically appropriate.
Follow-up
Patients were reviewed at 1 month, 3 months and 6 months after the end of the run-in period and thereafter at 6-monthly intervals. Patients allocated to intervention underwent the appropriate procedure as soon as possible after the 4-week 'baseline' visit. At each visit measurements were made of BP and serum creatinine and major events were recordedmyocardial infarction, stroke, episodes of cardiac failure, and death or dialysis. BP was measured in the sitting position with either a standard or Hawksley random zero sphygmomanometer by an observer unaware of the allocation to intervention or medical therapy.
During follow-up, the local clinician made decisions about changing anti-hypertensive drug therapy according to tolerability and BP levels. Clinicians were encouraged to 'step down' treatment if BP levels permitted, with a view to minimising therapy and discontinuing drugs if possible. Individual drug therapy and dosages were recorded at each visit. The principal analysis included the number of anti-hypertensive drugs used at each visit. Combined preparations-for example, combinations of loop and potassium sparing diuretics-were counted as two drugs.
Statistical considerations
The power calculations for this study were based on previously published data from similar patients from Glasgow and Newcastle. Based on a betweengroup standard deviation of the difference in mean arterial pressure of 12 mm Hg, it was estimated that it would be necessary to randomise 30 patients (P Ͻ 0.05) or 46 patients (P Ͻ 0.001).
The original intent was to restrict the study to patients with radiographic bilateral disease, but this was subsequently extended to patients with unilateral disease also and the decision made a priori to analyse the groups separately. The study was therefore conducted in respect of two parallel limbs with identical protocols so that three groups were identified-bilateral randomised, unilateral randomised and non-randomised.
The principal end-points were the differences in mean BP and serum creatinine between the 4-week run-in vist and 6-month follow-up. An analysis was also undertaken in respect of BP and serum creatinine at the last recorded visit for each patient, after adjustment for the follow-up times (range 3-54 months). Serum creatinine was not normally distributed and thus a non-parametric test was used to compare changes in creatinine. Regression analyses used log-transformed creatinine data.
Time to first recorded major event was analysed using the log rank test, both before and after correction for previous cardiovascular events using these as covariates in a Cox regression model.
Multiple stepwise regression analyses were performed in the predetermined subgroups and in the combined and randomised and non-randomised patients in an attempt to determine which clinical variables might affect outcome.
Results
During the period of recruitment 135 hypertensive patients with atheromatous renal artery stenosis were identified at the participating centres. Twentyeight patients with bilateral disease and 27 with unilateral disease were randomised. Demographic characteristics are summarised in Table 1 . Reasons for non-randomisation, apart from those prespecified, were severe aortic disease including aneurysm and aorto-iliac occlusion (19), patient unwilling (14), BP well controlled on minimal therapy (12) , patient aged Ͼ70 (10), critical renal status (6), consultant unwilling (4), multiple medical problems (4), renal artery occlusion (4), unstable BP (3), technically unsuitable (2), patient died before randomisation (2).
In the bilateral group randomised to intervention, one patient had a nephrectomy and one a vein bypass. In the unilateral group randomised to intervention, two patients underwent nephrectomy and one a vein bypass. All other randomised patients had percutaneous angioplasty. None of the patients randomised to medical therapy had an interventional procedure. In the non-randomised group, 20 patients had PCTA, seven vein bypass and two nephrectomy. Five patients (9.3%) in the combined intervention group and five patients (6.2%) in the combined medical group had an angioplasty during the followup phase.
Blood pressure changes (Table 2)
There was a consistent, clinically important fall in BP in all groups between referral and end of the runin phase.
In the bilateral randomised group, intervention was associated with a further decline in BP during follow-up, whereas little change was observed in those treated medically. At 6 months the difference in BP change between the two groups did not reach statistical significance. When the changes in BP at most recent follow-up (3-54 months) were compared a statistically significant difference in systolic BP was observed (P Ͻ 0.05). This difference persisted after adjustment for follow-up time for each patient (P Ͻ 0.18). The mean fall in BP at last followup in the intervention group, corrected for the medical group response, was 26/10 mm Hg.
In the unilateral randomised group, no statistically significant or clinically important differences were observed between the two groups. If anything, the systolic BP fell more in the medical than in the intervention group.
In the non-randomised patients, no important differences were observed between the intervention patients and the medical patients, either at 6 months or most recent follow-up.
Anti-hypertensive drug use
In both of the randomised groups changes in the number of drugs used were small, clinically unimportant and statistically insignificant. In the nonrandomised group there was a tendency for more drugs to be used during follow-up in the medical group (mean number at baseline 2.4, at 6 months 2.6, and at most recent follow-up 2.7). By contrast, in the intervention group there was a significant reduction in the average number of drugs used from When the BP recorded at the most recent visit was compared with the 4-week run-in data there was a statistically significant difference in systolic BP between the two treatment groups (*P Ͻ 0.005). This difference was also seen when the mean differences in systolic BP were adjusted for follow-up time in each patient (**P = 0.018). The mean differences between the BP at run-in and most recent visit were adjusted for follow up time for each patient. 2.8 at baseline to 2.3 at 6 months (P = 0.003) and 2.3 at the most recent visit (P = 0.014).
Unilateral, randomised

Non-randomised
Serum creatinine
Mean serum creatinine values are shown in Table  3 . The considerable spread of baseline of creatinine values in all groups is reflected in the large standard deviations. No significant differences, or trend in serum creatinine were observed between or within the groups during follow-up.
Angiography
Of the 40 patients undergoing angioplasty, 14 had repeat digital subtraction angiography (DSA) at an interval of at least 12 months, and eight patients in the medical group had a similar procedure. In the PCTA subgroup nine (64%) were categorised as improved, three (21%) as worse, and two (14%) as unchanged. In the medical subgroup one was categorised as better, one worse and six (75%) unchanged.
Major events
Among the 25 randomised patients assigned to intervention the following major events occurred during follow-up: heart failure (3), stroke (1), renal failure (2), myocardial infarction (1) and death or dialysis (2) . The corresponding numbers among the 30 randomised to medical therapy were heart failure (4), stroke (4), renal failure (2), myocardial infarction and deaths or dialysis (4). In the Cox regression model, when time to first major event per patient only was included, event-free survival tended to be longer in the intervention group. However, after adjustment for age, smoking, previous cardiovascular disease and heart failure, the survival function in the two groups, for all randomised patients combined, is virtually identical (Figure 1 ).
Multiple regression analysis
In a combined analysis of all 135 patients, systolic BP, diastolic BP, number of anti-hypertensive drugs and serum creatinine at the most recent follow-up visit were directly influenced by their respective values at baseline-ie, patients with high values during run-in tended to have the highest values at their most recent visit. Patients with higher systolic pressure at the end of the run-in period and those allocated to medical therapy also required more anti-hypertensive drugs during follow-up. In the bilateral randomised group, patients who were older at recruitment, and who had a more severe index of stenosis, tended to have higher BP during followup. Otherwise, the degree of stenosis, the need for a second procedure, sex, age, smoking habit, use of aspirin, and follow-up time did not influence outcome.
Complications
During the period of the study PCTA was performed in 40 out of 135 patients, 11 of whom suffered one or more serious or potentially serious complications directly attributable to the procedure. Eight patients (20%) suffered bleeding at the arterial site that was either difficult to control or resulted in a significant symptomatic haematoma. Four patients (10%) complained of pain that was sufficiently severe to require the administration of a narcotic analgesic. No dissections, perforations or renal artery thromboses were recorded but two patients developed renal failure requiring dialysis. Two patients suffered a stroke during their admission to hospital and one patient developed symptomatic hypotension after the procedure. No deaths occurred within 1 month of intervention.
Discussion
To our knowledge, this is the first report of a prospective randomised trial comparing intervention with medical therapy for hypertensive patients with renal artery stenosis. Our results suggested that PCTA results in an improvement in systolic BP in patients with bilateral atheromatous disease. We have been unable to demonstrate any benefit in respect of renal function or event-free survival. Complications of the procedure were an important source of morbidity, even in the hands of experienced radiologists in specialist centres. A recent randomised trial in patients with unilateral disease has reported very similar results. 8 Almost without exception, previous uncontrolled reports of the results of intervention in this disease have claimed improvements in BP control. Selective referral of patients to tertiary referral centres, and possible publication bias whereby 'positive' rather than 'negative' reports appear in print, may influence the perceived value of the technique reported. Unfortunately there has been a lack of standardisation of the methods of BP measurement, and, critically, a failure to take into account regression to the mean from the time of referral. Our data demonstrate very clearly the substantial fall in BP that can be observed simply by a short period of structured follow-up with no intervention or change of therapy, even in patients who may have been in regular attendance at hypertension clinics. This 'run-in' period to establish a baseline is an essential part of any study to evaluate changes in BP and is just as important in a trial of intervention as it would be in a trial of a new anti-hypertensive drug.
None of our patients was 'cured' in the sense of achieving normal BP off all drug therapy. We agree with Ramsay et al 5 that the classification of BP as 'improved'-so often used in reports of intervention-is fraught with difficulties of definition, interpretation and the vagaries of regression to the mean. If the magnitude of the reduction in BP attributable to intervention in our bilateral randomised group is a genuine effect of PCTA, and if it can be sustained in the longer term, then it could well be clinically important. Our outcome analysis was over a relatively short follow-up period, though the data show not even a trend towards a difference in event rates. Prior to setting up this trial, however, our power calculations had suggested that in order to demonstrate a significant difference in mortality, several hundred patients would have been required and we had concluded that that particular end-point was beyond the scope of our trial.
The majority of patients were not randomised. A number of reasons had been prespecified but some additional reasons were given by the supervising clinicians. This raises questions of selectivity and whether or not the group of randomised patients are representative of the wider population of patients with renovascular disease. This, of course, is a problem with virtually all reports of angioplasty in this condition, and reflects the difficulty of conducting formal trials in such complex patients. We present here the demographic and outcome data of all patients assessed in our centres during the duration of the study, including those not randomised. There is little evidence that the non-randomised patients fare any better or worse than the non-randomised.
Our assignment of patients to the 'bilateral' or 'unilateral' category was on the basis of the radiological appearances. Inspection of the data on serum creatinine clearly shows that even in the 'unilateral' patients, renal function must have been impaired in a substantial number of patients. In most cases we suspect that this reflects contralateral hypertensive nephrosclerosis. Furthermore, in atheromatous renal artery stenosis patients almost always have evidence of aortic disease and patients with 'unilateral' stenosis may develop bilateral disease during follow-up. We think it unlikely that the 'bilateral' and 'unilateral' groups as defined in our study represent fundamentally different diseases, but rather a difference in degree of renal artery involvement by the same disease. We are puzzled at the apparent difference in BP response to intervention in the two groups, and can offer no immediately obvious explanation for this. We specifically designed our study to investigate the groups separately and felt obliged to maintain the distinction in the analysis of the principal end-points.
In a number of patients the hypertension may well have been 'essential' rather than renovascular in origin. In some the intervention may have failed to alleviate the stenosis. We did not perform translesional pressure gradient measurements and repeat angiography was performed in too few patients to be able to make a formal comparison of patency rates. From the data available, however, we can suggest that the angiographic appearances tended to be improved after intervention and showed little change in those treated medically.
There is convincing evidence from observational studies that atheromatous renal artery stenosis is a progressive disease, often accompanied by the development of vascular events elsewhere and associated with a greater mortality than in patients with uncomplicated hypertension. 1 Many procedures are technically feasible in such patients, including nephrectomy, autotransplantation, endarterectomy, bypass grafting and percutaneous angioplasty with or without stent insertion. Technical virtuosity does not necessarily mean that such procedures should be deployed universally in the management of this disease. There may well be a place for each of these options in selected patients (as was the case in several of our patients), but unfortunately there is little evidence from prospective trials or even parallel 'open label' comparisons that such procedures improve outcome in terms of BP control or preserved renal function, far less event-free survival. Stent insertion is the most recent development and is being adopted in many centres, though with more enthusiasm than unequivocal evidence of benefit. Observational reports [9] [10] [11] attest to the feasibility of this procedure, even in technically challenging patients, and one report 12 provides encouraging evidence of some preservation of renal function in selected patients with deteriorating renal function. A recent overview of all published reports of stenting for renal artery stenosis (410 stents in 372 patients) concluded that as few as 2% of patients may expect to achieve a diastolic BP of less than 90 mm Hg without drug therapy. 13 The undoubted morbidity from all of these procedures may be minimised by careful patient selection, rigorous preoperative and perioperative management and operator skill and experience, but problems still arise, even in the most experienced hands. 8 This should not surprise clinicians familiar with the degree of cardiovascular pathology so often encountered in such patients. This not only adds to the technical difficulties of intervention but also contributes to the problems associated with conducting randomised clinical trials.
Patients with atheromatous renal artery disease are frequently identified by nephrologists, cardiovascular physicians, vascular surgeons and radiologists. Our data suggest that PCTA does offer the prospect of improved BP control but the selection of patients for intervention will continue to tax the skills of all clinicians involved. Further prospective trials 7 are the most reliable means of acquiring the necessary information on which to base these difficult decisions. For the time being our data support the use of angioplasty in hypertensive renovascular disease as a reserve procedure for patients whose BP cannot be controlled by medical therapy, or for those whose renal function is deteriorating despite medical therapy, rather than as a primary form of intervention.
